KBC Group
MRTX

KBC Group’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

KBC Group’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-955
Closed -$56K – 1902
2023
Q4 		$56K Hold
955
– – ﹤0.01% 1449
2023
Q3 		$42K Buy
+955
New +$34.1K ﹤0.01% 1596

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

KBC Group's MRTX Position: Q1 2024 in Review

KBC Group sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 955 shares — an estimated $56K sold.

KBC Group first reported a position in MRTX in Q3 2023 and held it in 2 quarters. The position peaked at $56K in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • KBC Group reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • KBC Group sold 955 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $56K.
  • KBC Group first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2023 and held it in 2 quarters.
  • KBC Group's Mirati Therapeutics, Inc. Common Stock position peaked at $56K in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on KBC Group's 13F filing for Q1 2024, filed 8 May 2024.